石杉碱甲对酒依赖合并认知功能障碍患者的疗效评价

目的探讨石杉碱甲对酒依赖合并认知功能障碍患者疗效的影响。方法将存在认知功能障碍的60例酒依赖患者随机分为研究组（30例）及对照组（30例）,对照组给常规治疗,研究组在常规治疗基础上给予石杉碱甲200μg/d,疗程8周。治疗前后采用韦氏成人智力量表（WAIS-RC）及韦氏记忆测验量表（WPS-R）评定认知功能障碍状况、治疗依从性、生存质量及不良反应。结果石杉碱甲治疗8周,研究组WAIS-RC及WPS-R评分、治疗依从性、生存质量的生理、心理、社会、环境各领域评分与对照组比较均明显升高（87.92比80.03,P〈0.05;80.28分比71.48分,P〈0.01;55.17%比27.59%,P〈0.05;14.18分比12.69分,P〈0.05;13.78分比12.31分,P〈0.05;14.66分比13.31分,P〈0.05;14.21分比12.48分,P〈0.01）。两组均无严重不良反应发生。结论石杉碱甲治疗酒依赖合并认知功能障碍疗效肯定、安全有效,并能提高生存质量。

Efficacy of Huperzine A in treating patients with alcohol dependence combined with cognitive impairment

Objective To investigate the influence on efficacy of Huperzine A treating cognitive impairment in patients with alcohol dependence. Methods A total of 60 patients were randomly divided into control group （30 cases） and study group （30 cases） for treatment 8 weeks. In the control group only conventional drugs were used, while in the study group 200 μg/d of Huperzine A was given besides the routine treatment. The efficacy and side effects were assessd using WAIS-RC, WPS-R, the treating dependence and treatment emergent symptom scale （TESS） before and after treatment week 8. Results Compare with the control group,the scores of WAIS-RC,WPS-R and the treating dependence were heightened significantly （87.92 scores vs 80.03 scores, P 〈 0.05; 80.28 scores vs 71.48 scores, P 〈 0.01; 55.17% vs 27.59%, P 〈 0.05; 14.18 scores vs 12.69 scores, P 〈 0.05; 13.78 scores vs 12.31 scores, P 〈 0.05; 14.66 scores vs 13.31 scores, P 〈 0.05; 14.21 scores vs 12.48 scores, P 〈 0.01） in the study group. No severe side-effects occurred. Conclusion Huperzine A is effective and safe in the treatment of cognitive impairment in patients with Alcohol dependence, and improve their quality of life.